Evidence map›Paper›PMID 37789229›Full record

ArticleAdvances in therapy2023

Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

Raymond Wong, Jesse Fishman, Koo Wilson, Michael Yeh, Mohammed Al-Adhami, Abigail Zion, Christopher W Yee, Lynn Huynh, Mei Sheng Duh

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Raymond WongSir Y.K. Pao Centre for Cancer and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong.
Jesse FishmanApellis Pharmaceuticals, Inc., 100 5th Avenue, Waltham, MA, 02451, USA.
Koo WilsonSwedish Orphan Biovitrum AB, Tomtebodavägen 23a, Solna, 171 65, Stockholm, Sweden.
Michael YehApellis Pharmaceuticals, Inc., 100 5th Avenue, Waltham, MA, 02451, USA.
Mohammed Al-AdhamiApellis Pharmaceuticals, Inc., 100 5th Avenue, Waltham, MA, 02451, USA.
Abigail ZionAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Christopher W YeeAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Lynn HuynhAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Lynn.Huynh@analysisgroup.com.ORCID http://orcid.org/0000-0003-3110-6775
Mei Sheng DuhAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Analysis Group (United States) · USApellis Pharmaceuticals (United States) · USChinese University of Hong Kong · HKSwedish Orphan Biovitrum (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37789229
PMCPMC10611589
OpenAlexW4387297715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.